Methyl[1-{2-[5-(10-{2-[1-{2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1h-imidazol-5-yl}-6-phenylindolo[1,2-c][1,3]benzoxazin-3-yl)-1h-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate and pharmaceutical compositions for inhibiting hcv replication comprising it
Methyl[1-{2-[5-(10-{2-[1-{2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1h-imidazol-5-yl}-6-phenylindolo[1,2-c][1,3]benzoxazin-3-yl)-1h-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate and pharmaceutical compositions for inhibiting hcv replication comprising it
Номер патента: IL215094A Опубликовано: 31-07-2016 Автор(ы): Принадлежит:Merck Sharp & Dohme
Gpr40 receptor agonist, methods of preparing same, and pharmaceutical compositions containing same as active ingredient
Номер патента: RU2650506C2. Автор: Сеунг Йуп ПАЕК,Сунг Бае ЛИ,Сеунг Хиун ЙООН,Соок Киунг ЙООН,Дзеунг Соон ЧОЙ. Владелец: ЭлДжи КЕМ, ЛТД.. Дата публикации: 2018-04-16.